Inequities in the Treatment of Cardiogenic Shock Associated with Acute Myocardial Infarction
Overview
This study evaluates the treatment capacity and management practices for acute myocardial infarction complicated by cardiogenic shock (AMI-CS) across various hospitals in Beijing. It highlights significant disparities in resource distribution and management approaches among different healthcare institutions.
Background
Cardiogenic shock is a critical condition with high mortality rates, particularly when associated with acute myocardial infarction. Understanding the management practices and resource allocation in different healthcare settings is essential. This study aims to provide insights into the current state of AMI-CS management in Beijing.
Data Highlights
The study included responses from 89 hospitals in Beijing, revealing that:
Only 45% of hospitals had access to advanced cardiac life support (ACLS) training for staff.
Emergency revascularization capabilities varied, with only 60% of hospitals offering percutaneous coronary intervention (PCI) on-site.
Multidisciplinary teams for AMI-CS management were present in 55% of hospitals.
There was a significant variation in the availability of mechanical circulatory support devices across hospitals.
Key Findings
Cardiogenic shock is predominantly caused by acute myocardial infarction, with a mortality rate of 40%-50%.
The study utilized a questionnaire adapted from an international survey to assess AMI-CS management practices.
Data were collected from 89 hospitals across Beijing, focusing on their capacity for emergency revascularization and multidisciplinary collaboration.
Significant inter-hospital differences in CS management were identified.
Clinical Implications
The disparities in treatment practices for AMI-CS across hospitals in Beijing highlight the necessity for standardized management protocols.
Conclusion
The authors concluded that the significant inequities in the treatment of AMI-CS in Beijing necessitate urgent attention to improve outcomes for patients. They emphasized the need for the establishment of standardized protocols and guidelines to ensure equitable access to advanced treatment options across all hospitals. Additionally, the study advocates for increased training and resources to enhance the capacity of healthcare providers in managing AMI-CS effectively. Future research should focus on developing targeted interventions to address these disparities and improve the overall quality of care for patients experiencing cardiogenic shock.
Clinical Research in Cardiology, 2026 -- Timing of IABP initiation and its impact on outcomes in acute myocardial infarction with cardiogenic shock: insights from a bi-center retrospective study
Journal of Cardiac Failure, 2025 -- Mean Arterial Pressure and Mortality in Infarction-Related Cardiogenic Shock With and Without Cardiac Arrest: A Meta-Analysis
Frontiers in Neurology, 2026 -- Regional disparities and hospital performance patterns in acute stroke reperfusion: a multicenter study in Sichuan Province, China
Cardiogenic Shock | New England Journal of Medicine, 2023
2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes | JACC, 2024
Microaxial Flow Pump or Standard Care in Infarct-Related Cardiogenic Shock | New England Journal of Medicine, 2023
Cardiogenic Shock | New England Journal of Medicine
2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines | JACC
Microaxial Flow Pump or Standard Care in Infarct-Related Cardiogenic Shock | New England Journal of Medicine
The new option is indicated for CMV prophylaxis in pediatric kidney and heart transplant recipients, as well as adult CMV retinitis and transplant prophylaxis.
